关于HER2 neu阳性早期乳腺癌管理的实用共识建议。
Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer.
作者信息
Bahl A, Singh R, Wadhwa J, Gupta S, Ahmed M, Uppal P N, Parikh Purvish M, Aggarwal S
机构信息
Deparment of Medical Oncology, Max Hospital, New Delhi, India.
Department of Medical Oncology, Artemis Hospital, Gurugram, India.
出版信息
South Asian J Cancer. 2018 Apr-Jun;7(2):102-105. doi: 10.4103/sajc.sajc_111_18.
Abstract
Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations with regards to the use of these agents and the management of HER2 neu early breast cancer for the benefit of community oncologists.
摘要
HER2的过度表达通常被认为是一种不良预后特征，因为它伴随着乳腺癌死亡率的增加。然而，特异性靶向HER2的药物的开发改善了这些肿瘤患者的治疗。该专家组利用已发表文献的数据、实践经验以及一大批学术肿瘤学家的意见，就这些药物的使用以及HER2阳性早期乳腺癌的治疗达成了这些实用的共识建议，以造福社区肿瘤学家。
相似文献
1
Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer.
South Asian J Cancer. 2018 Apr-Jun;7(2):102-105. doi: 10.4103/sajc.sajc_111_18.
2
Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.
South Asian J Cancer. 2018 Apr-Jun;7(2):146-150. doi: 10.4103/sajc.sajc_123_18.
3
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
South Asian J Cancer. 2018 Apr-Jun;7(2):96-101. doi: 10.4103/sajc.sajc_110_18.
4
Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
BMC Cancer. 2023 Jul 31;23(1):714. doi: 10.1186/s12885-023-11121-9.
5
Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women.
South Asian J Cancer. 2018 Apr-Jun;7(2):123-126. doi: 10.4103/sajc.sajc_117_18.
6
ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer.
Indian J Cancer. 2014 Jan-Mar;51(1):73-9. doi: 10.4103/0019-509X.134650.
7
Practical consensus recommendations regarding the management of sentinel lymph node issues in early breast cancer.
South Asian J Cancer. 2018 Apr-Jun;7(2):132-136. doi: 10.4103/sajc.sajc_120_18.
8
Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer.
South Asian J Cancer. 2018 Apr-Jun;7(2):137-141. doi: 10.4103/sajc.sajc_121_18.
9
Practical consensus recommendations on management of triple-negative metastatic breast cancer.
South Asian J Cancer. 2018 Apr-Jun;7(2):127-131. doi: 10.4103/sajc.sajc_118_18.
10
Practical consensus recommendations on Her2 +ve breast cancer with solitary brain mets.
South Asian J Cancer. 2018 Apr-Jun;7(2):118-122. doi: 10.4103/sajc.sajc_116_18.
引用本文的文献
1
Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India.
Cureus. 2024 Dec 20;16(12):e76061. doi: 10.7759/cureus.76061. eCollection 2024 Dec.
2
A quality evaluation of the clinical practice guidelines on breast cancer using the RIGHT checklist.
Ann Transl Med. 2021 Jul;9(14):1174. doi: 10.21037/atm-21-2884.
3
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study.
Breast. 2021 Oct;59:67-75. doi: 10.1016/j.breast.2021.06.005. Epub 2021 Jun 18.
4
Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India.
Ecancermedicalscience. 2021 Mar 19;15:1207. doi: 10.3332/ecancer.2021.1207. eCollection 2021.
本文引用的文献
1
Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World.
Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):22-27. doi: 10.4103/0971-5851.203511.
2
Anthracycline Chemotherapy and Cardiotoxicity.
Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75. doi: 10.1007/s10557-016-6711-0.
3
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
Breast Cancer Res Treat. 2016 Jul;158(2):361-71. doi: 10.1007/s10549-016-3878-9. Epub 2016 Jun 29.
4
Cardiotoxicity of anthracycline therapy: current perspectives.
Arch Med Sci. 2016 Apr 1;12(2):428-35. doi: 10.5114/aoms.2016.59270. Epub 2016 Apr 12.
5
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23.
6
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281.
7
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
J Clin Oncol. 2014 Jul 10;32(20):2151-8. doi: 10.1200/JCO.2013.52.0858. Epub 2014 Jun 2.
8
For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
PLoS One. 2014 Jan 2;9(1):e83646. doi: 10.1371/journal.pone.0083646. eCollection 2014.
9
Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.
Asian Pac J Cancer Prev. 2013;14(4):2231-5. doi: 10.7314/apjcp.2013.14.4.2231.
10
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Breast Cancer Res Treat. 2013 Apr;138(2):427-35. doi: 10.1007/s10549-013-2469-2. Epub 2013 Mar 12.
Zotero 插件